Containment Level (CL) 3 laboratories and CL2/3 insectaries

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:11 publications

Grant number: MC_UU_00034/8

Grant search

Key facts

  • Disease

    Zika virus disease, Dengue
  • Start & end year

    2023
    2028
  • Known Financial Commitments (USD)

    $2,878,040
  • Funder

    UK Research and Innovation (UKRI)
  • Principal Investigator

    Dr. Benjamin Brennan
  • Research Location

    United Kingdom
  • Lead Research Institution

    University of Glasgow
  • Research Priority Alignment

    N/A
  • Research Category

    14

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Not applicable

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The CL3 laboratories allow for the study of high consequence hazard group (HG) 3 human or Specified Animal Pathogens Order (SAPO) 3 animal pathogens using in vitro and in vivo experimental models (e.g., mosquitoes, ticks, mice & hamsters) and can accommodate work on clinical samples known or suspected to contain HG2 or HG3 pathogens. These facilities contribute to the overall capacity of the CVR to conduct high containment work with multiple virus orders/families, with an agile structure that can respond rapidly if required. The CVR is now poised to expand the footprint of its containment facilities to conduct larger scale studies using small animal models to examine viral pathogenesis, transmission, anti-viral compounds and vaccine efficacy. Moreover, it will repurpose its capacity for storing clinical samples to create an outbreak laboratory that will primarily support the aims of the CVR Preparedness platform. The CL3 platform also underpins the work of the CRUSH screening hub, facilitating a plethora of translational projects involving HG3 or SAPO 3 pathogens. The CL2 and CL3 insectaries provide the capacity to breed mosquitoes and ticks (arthropod vectors) and infect them with HG2 (e.g., Zika virus) or HG3 (e.g., dengue virus) arboviruses. These state-of-the-art facilities are among the best in Europe, and integral to supporting both MRC core- and externally funded research programmes ranging from arthropod physiology (e.g., trade-offs between mosquito physiology and arbovirus infection), the biology of endosymbiosis and commensal pathogens (e.g., Wolbachia), interactions between ticks and tick-borne viruses, development of transgenic mosquitoes, and assessment of mosquito-borne disease risk in Scotland.

Publicationslinked via Europe PMC

NSm is a critical determinant for bunyavirus transmission between vertebrate and mosquito hosts.

Virus-like particles of louping ill virus elicit potent neutralizing antibodies targeting multimers of viral envelope protein.

Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants.

Bisbenzimide compounds inhibit the replication of prototype and pandemic potential poxviruses.

SARS-CoV-2 variants evolve convergent strategies to remodel the host response.

Phenotyping the virulence of SARS-CoV-2 variants in hamsters by digital pathology and machine learning.

SARS-CoV-2 spike protein induces endothelial inflammation via ACE2 independently of viral replication.

The Timing and Magnitude of the Type I Interferon Response Are Correlated with Disease Tolerance in Arbovirus Infection.

BTN3A3 evasion promotes the zoonotic potential of influenza A viruses.